$COO

Keel Paul A purchased $250K of COO

Keel Paul A purchased 4,701 shares of COOPER COMPANIES, INC. (COO) at $53.18 ($0.25M total) on 2026-09-11.

Original reporting
SEC EDGAR · Keel Paul A
Published Sep 15, 2026, 8:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 8:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$COO
Neutral
medium confidence
Mentioned
$COO
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$COONeutralLow
01

Why it matters

The Form 4 filing provides the first public disclosure of this insider purchase, but the amount is modest.

02

Market read

A routine insider buy with limited trading relevance; may be noted by quantitative insiders but unlikely to drive price.

03

What to watch

Potential upcoming product launches or contract wins not disclosed could make the buy more meaningful.

Relevance 5/10Novelty 4/10Timing: filed Sep 15 2026

Background

Cooper Companies, Inc. (COO) is a medical device and health‑care services firm listed on NYSE.

Company-level read

Ticker impact

$COONeutralMedium confidence
Context

Director Keel Paul A purchased 4,701 COO shares at $53.18, total $250K on Sep 11, 2026.

Expected impact

Minimal short‑term price effect; may provide slight upside bias.

Evidence & confidence

Purchase amount is under $1M and represents a tiny fraction of outstanding shares, limiting market impact.

Market effects

Insider activity in healthcare distribution sector is routine; no broader sector shift.

Limited to US investors tracking COO; no regional ripple.

Negligible global impact.

Counterpoint

The purchase could be a window‑dressing move rather than genuine confidence.

Key entities

  • Cooper Companies, Inc.

    Issuer of the shares purchased.

  • Keel Paul A

    Director of COO who made the purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$COOMedAI 8/10

A Failed Auction and a 15% Drop: Is Cooper Companies (COO) a Value Trap or a Bargain?

Cooper Companies (COO) ended its 9-month effort to sell CooperSurgical after bids undervalued the business, according to management. The stock dropped 15% to a 52-week low near $51 after a Q3 miss and cut outlook. The company's core contact lens business, CooperVision, posted flat organic revenue growth, contributing to the guidance cut. Management authorized a $1B share repurchase program, while Bank of America questioned the valuation. COO reported record Q3 free cash flow of $273M.

$COOMedAI 8/10

The Cooper Companies (COO) Faces Near-Term Pressure from Slowing Contact Lens Demand

The Cooper Companies (COO) lowered its fiscal 2026 profit and revenue forecasts due to weaker-than-expected contact lens demand, with adjusted EPS now expected at $4.51–$4.55 and revenue at $4.23–$4.25 billion. Q3 revenue was $1.07 billion, missing estimates, though adjusted EPS beat at $1.15. The company cited U.S. channel inventory reductions as a key factor and decided to retain CooperSurgical.

$COOMedAI 8/10

Cooper Companies (COO) Bets on Fertility Growth Despite Weakness in CooperVision

Cooper Companies (COO) reported Q3 FY2026 revenue of $1.066B, up 1%, and adjusted EPS of $1.15, up 4%. The company spent $339.1M on share buybacks and has $1.5B remaining in repurchase capacity. Fertility segment growth and strong cash flow offset weakness in CooperVision, which saw flat organic growth and revenue declines in Americas and Asia Pacific. Gross margin improved to 67% on a GAAP basis, while adjusted operating margin rose 30 basis points to 26%.

$COOMed

Why Cooper, Freeport-McMoRan, and Baker Hughes Plunged

Cooper Companies (COO) fell 14.67% after reporting Q3 revenue of $1.07B and Q4 guidance below estimates. Freeport-McMoRan (FCX) dropped 6.59% due to White House uncertainty on copper tariffs. Baker Hughes (BKR) declined 6.66% despite raising its full-year revenue guidance to $28.5B-$30.3B.

$COOMedAI 8/10

COO Q2 Deep Dive: Inventory Actions and Strategic Review Shape Guidance

CooperCompanies reported Q2 revenue of $1.07B (flat YoY, 2.9% miss) and adjusted EPS of $1.15 (2.7% beat). Full-year guidance was lowered to $4.24B revenue and $4.53 EPS. The company reduced U.S. inventory and retained CooperSurgical after a strategic review. Management plans to invest in sales and R&D, aiming for future growth and improved margins.

$COOMedAI 8/10

Why is CooperCompanies Stock Down 15% Today?

CooperCompanies (COO) shares dropped 13.9% after Q3 earnings beat estimates but Q4 guidance fell short of expectations. The company also decided to retain CooperSurgical, removing a potential deal catalyst. U.S. distributor destocking is expected to continue impacting CooperVision's Q4 performance.